Clinical Research Directory
Browse clinical research sites, groups, and studies.
PRospective Multiple Myeloma Impact Study
Sponsor: SkylineDx
Summary
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
Official title: Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2018-02-27
Completion Date
2026-09-01
Last Updated
2024-12-03
Healthy Volunteers
No
Conditions
Interventions
MMprofiler SKY92 gene signature
MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 "high-risk" gene signature to aid in the determination of the Multiple Myeloma patient's prognosis
Locations (9)
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
New York Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York, United States
Columbia University Medical Center
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Wake Forest Baptist Medical Center,
Winston-Salem, North Carolina, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States